FDA Update Recommendations for Those Who Received Products from NECC

The FDA is reiterating and updating its previous recommendation that follow-up with patients be done when the following three conditions are met:

  • The medication was an injectable product purchased from or produced by NECC, including an ophthalmic drug that is injectable or used in conjunction with eye surgery, or a cardioplegic solution,
  • The medication was shipped by NECC on or after May 21, 2012, and
  • The medication was administered to patients on or after May 21, 2012.

Please review the new recommendations on the FDA website http://www.fda.gov/Drugs/DrugSafety/ucm322734.htm. Given the quickly evolving investigation, consider monitoring the website daily for further updates.

 The NC Department of Public Health together with the Board of Pharmacy, will be calling the 103 facilities the FDA originally identified as receiving products from NECC on or after May 21, 2012 to notify them of these changes.


Share this Post